Background: Pain is an unpleasant complication commonly observed following congenital heart surgery, but is not often treated properly.
Background
Pain is a common complication after congenital heart surgery with lots of challenges for the children, their parents and the health care providers.
Furthermore, it is often underdiagnosed and therefore not treated properly. Inappropriate management of postoperative pain is associated with deleterious effects including inadequate cough and clearance of pulmonary secretions and atelectasis especially in children, following heart surgery.
Opioids are often used to manage postoperative pain; nevertheless, they are associated with many adverse effects such as respiratory and cardiovascular depression. Therefore, use of non-opioid analgesics is popular among physicians caring for children undergoing cardiac surgery.
Paracetamol is a non-opioid analgesic commonly used to manage postoperative pain for different surgeries in children. It is used effectively and safely for pain relief after adult (1, 2) and pediatric heart surgeries (3).
Non-steroidal anti-inflammatory drugs (NSAID) are used to control postoperative pain. However, their safety is questioned in children undergoing heart surgery. Ketorolac has been used safely to manage postoperative pain in different pediatric surgeries (3) (4) (5) (6) (7) (8) including congenital heart surgery (9-11) with no adverse effects.
Objectives
The current study aimed to compare paracetamol and ketorolac in management of postoperative pain in congenital heart surgery. The primary outcome was comparison of pain score in the two groups. The secondary outcome included investigation of additional postoperative analgesic requirements and adverse effects including postoperative bleeding, acute kidney injury, gastrointestinal discomfort and bleeding following administration of the two drugs.
Methods
Eighty-one children over one year weighting more than 10 kg undergoing congenital heart surgery were recruited for the study. The ethics committee of Mashhad University of Medical Sciences approved the study and parents signed written informed consent forms before recruitment of their children. Using a computer based randomization, the patients were allocated to either intravenous paracetamol (n = 45) or ketorolac (n = 36) groups. The exclusion criteria were history of drug allergy, renal or hepatic insufficiency, unusual intraoperative or postoperative bleeding requiring blood products and peptic ulcer disease.
The patients in the paracetamol group received intravenous paracetamol 15 mg/kg every six and eight hours on days one and two, respectively.
Subjects in the ketorolac group received intravenous ketorolac 0.5 mg/kg every six and eight hours on days one and two, respectively.
The patients were evaluated for pain using critical pain objective tool (CPOT) ( Figure 1 ) while intubated; and the face, legs, activity, cry, consolability (FLACC) scoring system (Table 1 ) when extubated at one hour intervals for 10 hours and every four hours up to 48 hours. They were given fentanyl 1µg/kg for CPOT of 6 -8 and FLACC of 6 -8 and 0.5 µg /kg for CPOT of 3 -5 and FLACC of 3 -5.
The patients were also evaluated for development of adverse drug effects including postoperative bleeding, acute kidney injury using modified pediatric RIFLE (risk, injury, failure, loss of kidney function and end-stage kidney disease) criteria (Table 2) , and gastrointestinal discomfort and bleeding.
The patients underwent a standard anesthesia with ketamine 1 mg/kg, midazolam 0.1 mg/kg, and fentanyl [1] [2] [3] [4] [5] µg/kg for induction and atracurium 0.6 mg/kg to facilitate endotracheal intubation. Anesthesia was maintained with isoflurane 1.2 -2.5 minimum alveolar concentration (MAC) and additional fentanyl 5 µg/kg to maintain blood pressure and heart rates at 20% from baseline. Atracurium was given as 0.2 -0.4 mg/kg/hour. The patients were transferred to the intensive care unit (ICU) while intubated where they were weaned from mechanical ventilation and extubated under a standard protocol. The children were under a standard monitoring including electrocardiography, invasive blood pressure, central venous pressure, end-tidal CO 2 , hear rates, respiratory rates and temperature.
A difference of 20% in pain intensity was considered clinically significant. A sample size of 68 was required to detect such a difference between the groups for a power of 90% at a significance level of 5%. The sample size was increased to 80 in case of missing data. Data analyses were performed by SPSS software for Windows, version 16 (SPSS Inc, Chicago, IL, USA). Mean and standard deviation values for different variables were calculated. Independent Student T-test was used to compare continuous variables exhibiting normal distribution, and Chi-square or the Fisher exact tests for non-continuous variables. A P-value < 0.05 was considered significant.
Results
Eighty-one patients were recruited for the study with the mean age of 50.40 ± 23.80 months. The patients were similar in both groups with respect to demographic characteristics (Table 3) .
There were no significant differences between the two groups regarding duration of surgery, frequency of on pump surgery, cardiopulmonary pump and cross clamp time (Table 3) .
Based on CPOT scale, pain score was significantly lower in the ketorolac (3.25 ± 2.48) than paracetamol group (5.22 ± 5.48) (P-value = 0.049) (Figure 2 ). The mean FLACC scores were 5.33 ± 3.77 and 8.02 ± 7.44
in the ketorolac and paracetamol groups, respectively (Pvalue = 0.05) on the first postoperative day. On the second day, patients in the ketorolac group had FLACC score of 0.55 ± 1.99 and the ones in the paracetamol group had FLACC score of 2.82 ± 3.88 (P-value = 0.01) (Figure 3 ).
Patients in the ketorolac group required less fentanyl The patients were similar with respect to development of acute kidney injury (AKI). No cases of gastrointestinal discomfort and bleeding were observed in the groups.
Discussion
The current study revealed that ketorolac was more effective than paracetamol to manage postoperative pain in children undergoing cardiac surgery. In addition, it can reduce postoperative additional analgesic requirement in comparison to paracetamol with no additional adverse effects.
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Arch Crit Care Med. 2016; 1(4):e8278. Similar to the current study findings, some studies reported that paracetamol and ketorolac were both effective to manage postoperative pain following thyroidectomy (12) and parathyroidectomy (13) . However, in the current series ketorolac was more effective in reducing pain; indicating that ketorolac was more effective in reducing moderate to severe pain experienced during cardiac surgery.
The obtained results showed that ketorolac reduced additional analgesic requirement postoperatively even better than paracetamol. It was in agreement with the report of Inoue et al. (10) . Similar to the current study but in a different population, Burd et al. (14) and Chauhan et al. (15) also found that ketorolac was able to reduce the amount of additional postoperative opioid required after surgery in infants (14, 15) .
In contrast to the current study, it was reported that patients with renal colic receiving paracetamol required less additional opioids in comparison to the ones in the ketorolac group (16) . Different types of surgeries might explain this discrepancy. Application of nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative period can be associated with hemostasis disturbance, pulmonary, gastrointestinal and renal dysfunction (11, 13, 17) . However, several investigations demonstrated safety of ketorolac regarding renal dysfunction following pediatric heart surgery (10, 11).
It is reported that single use of ketorolac is effective and safe in infants less than two years (14, 18) . Furthermore, ketorolac had no adverse effects on wound healing (19) and perioperative bleeding (19, 20) in infants undergoing cardiac surgery.
Use of ketorolac was not associated with increased risk of renal dysfunction in the current series. It was confirmed by other studies (10, 11) . In agreement with the current study, Jalkut et al. suggested that ketorolac could be used in specific pediatric patients after cardiac surgery with minimal risk of bleeding or renal dysfunction with appropriate dosing and duration of use (9) .
In contrast, it is reported that the concomitant use of aspirin with ketorolac is associated with increased renal morbidity in small infants' post-cardiac surgery (21) . However, the current study did not evaluate the effect of this combination on renal dysfunction.
Bleeding is proposed as a potential adverse effect of NSAIDs. However, there are a number of studies indicating that using ketorolac to manage postoperative pain in children after cardiac surgery does not increase the risk of postoperative bleeding (11, 19, 22, 23) . Similarly, in our patients no significant postoperative bleeding was noticed in the ketorolac in comparison to the paracetamol group.
The current study had a few limitations. Distribution of surgeries was not similar in the two groups that might affect the nature and intensity of pain. Furthermore, amount of intraoperative opioids was not investigated in the two groups that might affect their postoperative pain and analgesic requirements.
It was concluded that both ketorolac and paracetamol can reduce pain intensity effectively and safely after pediatric heart surgery with no preference. However, more additional analgesic was required in the paracetamol group in the first two postoperative days. Furthermore, ketorolac was not associated with increased risk of renal dysfunction, gastrointestinal discomfort and postoperative bleeding.
